The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has
been a model for cancer therapy development. Though most patients with CML have a …

The truncated chromosome 22 that results from the reciprocal translocation t (9; 22)(q34;
q11) is known as the Philadelphia chromosome (Ph) and is a hallmark of chronic myeloid …

Abstract STOP second generation (2G)–tyrosine kinase inhibitor (TKI) is a multicenter
observational study designed to evaluate 2G-TKI discontinuation in chronic myeloid …

Chronic myeloid leukemia (CML) is caused by BCRABL1 in a cell with the biological
potential, intrinsic or acquired, to cause leukemia. This cell is commonly termed the CML …

Summary Protein phosphatase 2A (PP2A), one of the main serine–threonine phosphatases
in mammalian cells, maintains cell homoeostasis by counteracting most of the kinase-driven …

The cancer stem cell (CSC) concept, which arose more than a decade ago, proposed that
tumor growth is sustained by a subpopulation of highly malignant cancerous cells. These …

Genomic events associated with poor outcome in chronic myeloid leukemia (CML) are
poorly understood. We performed whole-exome sequencing, copy-number variation, and/or …

Chronic myeloid leukaemia (CML) is a myeloproliferative disorder arising in the
haemopoietic stem cell (HSC) compartment. This disease is characterised by a reciprocal t …

We characterized leukemia stem cells (LSC) in chronic phase chronic myelogenous
leukemia (CML) using a transgenic mouse model. LSC were restricted to cells with long …

Using a mouse model recapitulating the main features of human chronic myelogenous
leukemia (CML), we uncover the hierarchy of leukemic stem and progenitor cells …